HPV16
-
Immunotherapeutic Efficacy of Vaccines Generated by Fusion of Dendritic Cells and HPV16-Associated Tumour Cells
Jana Šímová, J. Bubeník, J. Bieblová, M. Indrová, T. Jandlová
2005, Vol. 51, Issue 1, pp. 19-24 -
The Role of NK1.1+ Cells in the Protection against MHC Class I+ HPV16-Associated Tumours
Jana Šímová, J. Bubeník, J. Bieblová, T. Jandlová
2004, Vol. 50, Issue 6, pp. 200-202 -
Adjuvant Cytokine Treatment of Minimal Residual Disease after Surgical Therapy in Mice Carrying HPV16-Associated Tumours: Cytolytic Activity of Spleen Cells from Tumour Regressors
Marie Indrová, R. Mikyšková, T. Jandlová, V. Vonka, J. Bubeník, J. Bieblová
2003, Vol. 49, Issue 6, pp. 217-222 -
Immunotherapy of HPV 16-Associated Tumours with Tumour Cell Line/Dendritic Cell Line (TC-1/DC2.4) Hybrid Vaccines
Jana Šímová, J. Bieblová, T. Jandlová, J. Bubeník
2003, Vol. 49, Issue 5, pp. 203-206
